Content by PRECOS

There is a growing need within the pharmaceutical and biotech industries for more “challenging” preclinical modeling for cancer drug development. It is essential to use patient-relevant models to evaluate the cancer medicines of the future in order to ensure that preclinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients.